DITTO Daily has raised £1.35 million in pre-seed funding to expand its science-led supplement range to address menstrual symptoms, following strong market traction since its launch earlier this year. The company is addressing a significant disconnect between menstrual health research and evidence-based solutions available to women.
The round was led by Eka Ventures, with participation from notable investors including Jean-Baptise Wautier. The investment will support continued scientific research, solution-oriented innovation, and channel expansion, as DITTO scales its science-first approach to menstrual health.
Founded in 2024 by nutrition scientist Alice van der Schoot, DITTO developed the Cycle Supplement to comprehensively target both the mental and physical challenges of the menstrual cycle – addressing a significant unmet need.
Alice van der Schoot, Founder of DITTO Daily, said: “For too long, there has been a huge disconnect between what science understands and the solutions available to those suffering from cycle-related symptoms. Too many are given outdated advice or left to navigate trial and error with ineffective approaches.
At DITTO, we’re setting a new standard in how we understand and manage menstrual cycles through a science-led approach, ensuring women have access to the solutions they deserve. This funding allows us to accelerate our research and deliver more evidence-based solutions to the billions of women who need them.”
The supplement is formulated with 10 carefully selected ingredients with the strongest clinical evidence for menstrual cycle symptom relief. It features an innovative nutrient delivery biotechnology, “beadlet-in-oil,” designed to enhance nutrient absorption.
Since launching in the UK four months ago, the supplement has seen significant uptake, particularly among those with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The Cycle Supplement has demonstrated strong clinical validation, with a recent clinical trial showing 88% of participants experienced a reduction in overall symptom severity.
This is echoed by user reviews that consistently highlight its positive impact on menstrual cramps, mood swings, bloating, and energy levels.
In the past 6 months, DITTO have built a highly engaged online community of over 110,000 across Instagram and TikTok where they are committed to making research accessible, helping women to better understand and manage their cycles.
Moving forward, DITTO plans to introduce new innovations to affirm their leadership in the menstrual health category, with 3 more clinical trials planned in the next year.
Camilla Dolan, General Partner at Eka Ventures, said “Eka is thrilled to lead DITTO Daily’s pre-seed round, backing Alice’s vision to translate cutting-edge academic science into mainstream, efficacious products that improve women’s daily health from the inside.
Early feedback and clinical results from DITTO Daily’s first product, Cycle supplement, demonstrates the unmet need in women’s health and the team’s ability to deliver fast, evidence-based impact.”
